PL3338791T3 - Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca - Google Patents

Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca

Info

Publication number
PL3338791T3
PL3338791T3 PL17209369T PL17209369T PL3338791T3 PL 3338791 T3 PL3338791 T3 PL 3338791T3 PL 17209369 T PL17209369 T PL 17209369T PL 17209369 T PL17209369 T PL 17209369T PL 3338791 T3 PL3338791 T3 PL 3338791T3
Authority
PL
Poland
Prior art keywords
neuregulin
prophylaxis
treatment
heart failure
therapeutic dosing
Prior art date
Application number
PL17209369T
Other languages
English (en)
Polish (pl)
Inventor
Anthony Caggiano
Anindita Ganguly
Jennifer Iaci
Tom Parry
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of PL3338791T3 publication Critical patent/PL3338791T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17209369T 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca PL3338791T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13517108P 2008-07-17 2008-07-17
EP17209369.2A EP3338791B1 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
PCT/US2009/004130 WO2010030317A2 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
EP09813336.6A EP2320933B1 (en) 2008-07-17 2009-07-17 Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure

Publications (1)

Publication Number Publication Date
PL3338791T3 true PL3338791T3 (pl) 2020-04-30

Family

ID=42005671

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17209369T PL3338791T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
PL09813336T PL2320933T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09813336T PL2320933T3 (pl) 2008-07-17 2009-07-17 Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca

Country Status (13)

Country Link
US (5) US20110166068A1 (enExample)
EP (3) EP3338791B1 (enExample)
JP (5) JP5797112B2 (enExample)
CN (3) CN104623633A (enExample)
AU (3) AU2009292216B2 (enExample)
BR (1) BRPI0916442A2 (enExample)
CA (1) CA2731113A1 (enExample)
DK (2) DK2320933T3 (enExample)
ES (2) ES2664394T3 (enExample)
MX (2) MX384378B (enExample)
PL (2) PL3338791T3 (enExample)
RU (4) RU2536938C2 (enExample)
WO (1) WO2010030317A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013149163A1 (en) * 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury
US20160129084A1 (en) * 2013-03-06 2016-05-12 Acorda Therapeutics, Inc. Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN111407882A (zh) * 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3353546A1 (en) 2015-09-25 2018-08-01 Douglas B. Sawyer Methods for treating cardiac injury
US11426447B2 (en) * 2016-04-19 2022-08-30 Leibniz-Institut Fur Alternsforschung—Fritz-Lipmann-Institut E.V. (Fli) Neuregulin for the treatment of tumors of the nervous system
CN110835368A (zh) * 2018-08-15 2020-02-25 上海泽生科技开发股份有限公司 神经调节蛋白多肽片段及其用途
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
WO2023070078A1 (en) * 2021-10-22 2023-04-27 The Research Institute At Nationwide Children's Hospital Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US6087323A (en) 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) * 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
WO2001034174A2 (en) 1999-11-12 2001-05-17 Entremed, Inc. Methods for administration of therapeutic agents on an antiangiogenic schedule
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
JP2005525317A (ja) 2002-01-18 2005-08-25 カイロン コーポレイション Ｈｅｒ２レセプタータンパク質の過剰発現によって特徴づけられる癌のための組み合わせｉｌ−２／抗ｈｅｒ２抗体治療
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20070010518A1 (en) * 2005-02-18 2007-01-11 Matti Kivikko Method for administering levosimendan
MX2007010603A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal.
CA2658326C (en) 2005-09-02 2013-04-23 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CN102026651B (zh) 2008-02-29 2015-06-03 阿索尔达治疗公司 达到所需胶质生长因子2血浆水平的方法
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
AU2010306777C1 (en) 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
WO2013149163A1 (en) 2012-03-30 2013-10-03 Acorda Therapeutics, Inc. Use of neuregulin to treat peripheral nerve injury

Also Published As

Publication number Publication date
EP3338791B1 (en) 2019-09-18
RU2536938C2 (ru) 2014-12-27
AU2017203528A1 (en) 2017-06-15
CN107019794B (zh) 2021-03-12
ES2763184T3 (es) 2020-05-27
US20110166068A1 (en) 2011-07-07
US20200009228A1 (en) 2020-01-09
JP2011528353A (ja) 2011-11-17
EP2320933A1 (en) 2011-05-18
WO2010030317A2 (en) 2010-03-18
JP6189879B2 (ja) 2017-08-30
JP2015129137A (ja) 2015-07-16
US20160113999A1 (en) 2016-04-28
CA2731113A1 (en) 2010-03-18
CN102159236A (zh) 2011-08-17
JP5797112B2 (ja) 2015-10-21
JP2019196370A (ja) 2019-11-14
AU2009292216B2 (en) 2015-03-05
AU2009292216A1 (en) 2010-03-18
RU2020111236A3 (enExample) 2021-09-21
CN107019794A (zh) 2017-08-08
DK2320933T3 (en) 2018-04-16
RU2719199C1 (ru) 2020-04-17
PL2320933T3 (pl) 2018-07-31
EP2320933A4 (en) 2013-02-27
BRPI0916442A2 (pt) 2018-06-19
AU2015202877A1 (en) 2015-06-18
RU2020111236A (ru) 2021-09-21
RU2011105821A (ru) 2012-08-27
EP3632459A1 (en) 2020-04-08
US9198951B2 (en) 2015-12-01
JP2022023208A (ja) 2022-02-07
US11235031B2 (en) 2022-02-01
ES2664394T3 (es) 2018-04-19
EP2320933B1 (en) 2017-12-27
EP3338791A1 (en) 2018-06-27
US20130324466A1 (en) 2013-12-05
US20180280477A1 (en) 2018-10-04
MX384378B (es) 2025-03-14
RU2698090C2 (ru) 2019-08-22
RU2014141514A (ru) 2016-05-10
MX2011000696A (es) 2011-07-29
AU2015202877B2 (en) 2017-03-09
JP2017200949A (ja) 2017-11-09
HK1256637A1 (en) 2019-09-27
US9956266B2 (en) 2018-05-01
CN104623633A (zh) 2015-05-20
DK3338791T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
IL259475A (en) Combined therapy for the treatment of diabetes
PL2320933T3 (pl) Terapeutyczne dawkowanie neureguliny lub jej subsekwencji do leczenia lub profilaktyki niewydolności serca
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
ZA201200373B (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
IL210959A0 (en) Respiratory disease treatment
GB0817207D0 (en) therapeutic apsac compounds and their use
AU324215S (en) Handpiece for massage or therapy
PL2247297T3 (pl) Działanie terapeutyczne w stanach chorobowych płuc
PT2424870E (pt) Agentes terapêuticos 713
IL205675A0 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
PL2424529T3 (pl) Nowe postępowania terapeutyczne z zastosowaniem centakwiny
GB0806047D0 (en) Treatment of heart failure
EP2269665A4 (en) VISIBLE MEDICAL TREATMENT MATERIAL
IL216717A (en) Use of benzidamine in the manufacture of a drug for the treatment of p40-dependent diseases
GB0814043D0 (en) The treatment of skin disorders
GB0804320D0 (en) Treatment of heart failure
GB0816662D0 (en) Treatment of heart failure
GB0816301D0 (en) Therapeutic treatments
GB0816300D0 (en) Therapeutic treatments
GB0915802D0 (en) Therapeutic treatments
GB0809319D0 (en) The treatment of puritus
GB0700886D0 (en) Medical treatment
GB0800489D0 (en) Therapeutic use
GB0800487D0 (en) Therapeutic use
GB0814488D0 (en) Respiratory disease treatment